Gliflozin

Jun 12, 2017

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction, and Stroke in the CANVAS Program

Jun 10, 2017

Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017

Jun 09, 2017

Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Jun 05, 2017

Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions